Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an announcement.
Prescient Therapeutics Limited announced a change in the director’s interest, with James Campbell acquiring 222,000 fully paid ordinary shares through an on-market trade. This change reflects a significant increase in the director’s stake, indicating confidence in the company’s future prospects and potentially impacting investor perceptions positively.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer treatments. The company specializes in targeted therapies and personalized medicine, aiming to improve patient outcomes in oncology.
YTD Price Performance: -6.00%
Average Trading Volume: 617,193
Technical Sentiment Signal: Hold
Current Market Cap: A$37.85M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.